Summary
Johnson & Johnson reported solid financial results for the nine months ended September 27, 2009, despite a slight year-over-year decrease in sales of 6.6% to $45.3 billion. This decline was primarily attributed to a significant negative currency impact of 6.7% and operational challenges in certain segments, particularly Pharmaceuticals. Net earnings remained strong at $10.1 billion, demonstrating the company's resilience. The company's balance sheet shows a healthy increase in total assets to $91.6 billion from $84.9 billion in the prior year, driven by growth in intangible assets and goodwill, reflecting strategic acquisitions. Cash flow from operations was robust at $11.3 billion, underscoring the company's ability to generate substantial cash to fund operations, dividends, and strategic investments. Key strategic moves during the period included significant acquisitions such as Mentor Corporation and Cougar Biotechnology, Inc., aimed at strengthening its product portfolio and market position, particularly in the medical devices and pharmaceutical sectors. The company also continues to manage significant legal and patent litigations, with ongoing developments in several high-profile cases related to its pharmaceutical and medical device products. Despite these challenges, Johnson & Johnson maintained its commitment to returning value to shareholders, evidenced by consistent dividend payments and a focus on operational efficiency and cost containment.
Financial Highlights
52 data points| Revenue | $15.08B |
| Cost of Revenue | $4.43B |
| Gross Profit | $10.65B |
| SG&A Expenses | $4.77B |
| Interest Expense | $142.00M |
| Net Income | $3.35B |
| EPS (Basic) | $1.21 |
| EPS (Diluted) | $1.20 |
| Shares Outstanding (Basic) | 2.76B |
| Shares Outstanding (Diluted) | 2.79B |
Key Highlights
- 1Total sales for the nine months ended September 27, 2009, were $45.3 billion, a 6.6% decrease from $48.6 billion in the prior year, impacted by a 6.7% negative currency effect.
- 2Net earnings for the nine months were $10.1 billion, a slight decrease from $10.2 billion in the prior year, with diluted EPS at $3.61 compared to $3.60.
- 3The company completed significant acquisitions during the period, including Mentor Corporation for $1.1 billion and Cougar Biotechnology, Inc. for $1.0 billion, enhancing its strategic positioning.
- 4Operating cash flow remained strong at $11.3 billion for the nine months, providing ample liquidity for operations and investments.
- 5The Pharmaceutical segment experienced a significant sales decline of 12.5% for the nine months, largely due to patent expirations and generic competition impacting key products like Topamax and Risperdal.
- 6The Medical Devices and Diagnostics segment showed resilience with a slight decrease of 1.3% in sales for the nine months, but saw an improvement in operating profit margin to 34.1%.
- 7Johnson & Johnson continues to actively manage a substantial portfolio of legal proceedings, including product liability claims and patent litigations, with ongoing developments in various significant cases.